• Eimad Shotar, Louis Meyblum, Kevin Premat, Stéphanie Lenck, Vincent Degos, Teodor Grand, Jonathan Cortese, Arnaud Pouvelle, Geoffroy Pouliquen, Samuel Mouyal, Anne-Laure Boch, Alexandre Carpentier, Nader-Antoine Sourour, Bertrand Mathon, and Frédéric Clarençon.
• Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France eimad.shotar@gmail.com.
• J Neurointerv Surg. 2020 Dec 1; 12 (12): 1209-1213.

BackgroundEmbolization of the middle meningeal artery (MMA) has emerged as a potential treatment of chronic subdural hematomas (CSDHs).ObjectiveTo evaluate the impact on recurrence rate of postsurgical embolization of CSDH in patients with a higher than average risk of recurrence.MethodsA monocentric retrospective study was performed on retrospectively collected data. From March 2018 to December 2019, embolization of the MMA was proposed as an adjunct postoperative treatment after burr-hole surgery in patients operated for a recurrent CSDH or a CSDH with an independent recurrence risk factor, including antiplatelet therapy, full anticoagulation therapy, coagulation disorder, hepatopathy, or chronic alcoholism. Patients who had undergone postoperative embolization were compared with a historic group of patients operated between March 2016 and March 2018, selected based on the same inclusion criteria.ResultsDuring the study period, 89 patients (with 74 unilateral and 15 bilateral CSDHs) were included and underwent an embolization procedure, leading to 91 out of a total of 104 MMA being embolized (88%). These were compared with 174 patients (138 unilateral and 36 bilateral CSDH) in the historic control group. One major procedure-related adverse event was registered. Four of the 89 patients (4%) required surgery for a CSDH recurrence in the embolization group, significantly less than the 24 of 174 patients (14%) in the control group (OR=0.28, 95% CI 0.07 to 0.86, p=0.02).ConclusionsPostsurgical embolization of the MMA may reduce the recurrence rate of CSDHs with a risk factor of recurrence.© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

32 keywords...

hide…